“Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma ” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s386. doi:10.25251/skin.8.supp.386.